Participated · Series D · May 2026

CellCentric is a privately held, clinical-stage biotech company developing inobrodib, an orally bioavailable p300/CBP inhibitor. The lead program is in registration-enabling clinical trials for patients with relapsed/refractory multiple myeloma, and the company is enrolling a Phase 2 DOMMINO-1 study in the UK and US. CellCentric plans to initiate the global Phase 3 DOMMINO-2 trial in the second half of 2026. The company holds an IP portfolio and has clinical collaborations and strategic partnerships that provide external validation. Led by CEO Will West, CellCentric is based in Cambridge, UK, and maintains an additional office in Boston, MA. The article did not disclose revenue or other operating metrics.

Participated · Series A · Oct 2025

Predicta Biosciences builds laboratory-developed tests that combine deep genomic and immune profiling to improve the diagnosis and management of blood cancers such as multiple myeloma. Its first product, GenoPredicta, launched in April and can be run on either peripheral blood or bone marrow to help physicians identify molecular drivers of disease and predict patient response to immunotherapies like CAR-T cells and bispecific antibodies. The company operates a CLIA-approved laboratory and plans to use new capital to expand both its team and lab infrastructure. Beyond diagnostics, Predicta intends to leverage its growing dataset to discover and commercialize precision therapeutics. The firm collaborates with clinical providers and advocacy groups, including the HealthTree Foundation, to accelerate adoption. Brian McKernan, a three-time biotech founder and former CEO of Fluent BioSciences, has been appointed CEO to steer commercialization and future product development. Financial metrics such as revenue or user numbers were not disclosed in the article.

Participated · Series B · Sep 2025

Mercy BioAnalytics develops extracellular vesicle–based liquid biopsy tests aimed at the early detection of cancer. Its patented Mercy Halo platform uses biomarker co-localization to interrogate abundant blood-based extracellular vesicles that carry cancer signatures from their cell of origin. The company’s initial focus is the early detection of ovarian and lung cancers, and its blood-based ovarian cancer test portfolio is designed to detect pre-clinical high grade serous ovarian carcinoma in post-menopausal women. Mercy says the Mercy Halo ovarian cancer screening test shows unprecedented sensitivity and specificity in a blinded evaluation of samples from a randomized controlled trial. The company plans to commercialize its ovarian cancer tests and expand the Mercy Halo portfolio to include multi-cancer and lung cancer screening tests. Mercy is based in Waltham, Mass., and recently closed a financing to support commercialization and portfolio expansion. Mercy BioAnalytics is advancing the Mercy Halo extracellular vesicle‑based liquid biopsy platform to enable early detection of cancer. Mercy Halo seeks high clinical sensitivity and specificity by simultaneously detecting multiple cancer‑related biomarkers co‑localized on individual tumor‑derived extracellular vesicles. The test can be run on a very small volume of serum or plasma and uses a simple PCR‑based readout. The company closed an oversubscribed $41 million Series A to advance development and commercialization, with an initial focus on high‑risk lung cancer screening. Proceeds will also support clinical programs in ovarian cancer and the development of a broader portfolio of early‑detection tests. Preliminary data presented at ASCO, AACR and EDCC demonstrated promising performance for detecting Stage I and II lung and ovarian cancers, and Mercy is planning larger independent validation studies.

Participated · Seed · May 2024

CatenaBio is a UC Berkeley spinout from the labs of Jennifer Doudna and Matt Francis focused on creating therapeutic structures that enable multiple kinds of payloads of any size and complexity. Its initial product area is first-in-class "multi payload conjugates" (MPCs™). The company positions its approach as rapidly escalating the effectiveness and usefulness of antibody-drug conjugates and enabling targeted combination therapies beyond current clinical options. CatenaBio plans to accelerate development of its lead asset, launch scale-up activities with leading CROs, and continue supporting business-development partnerships with biotech and pharma collaborators. The recently closed seed extension will extend runway to generate additional compelling data to support a Series A later this year. CEO Marco Lobba, Ph.D., said the funds will enable accelerated buildup of the MPC pipeline.

Participated · Series D · Dec 2021

Freenome develops blood-based screening tests for early cancer detection using a multiomics platform that combines computational biology, machine learning, and other technologies. Its initial programs focus on colorectal and lung cancers, with single-cancer and tailored multi-cancer tests under development. The platform is also being evaluated with biopharma and diagnostic partners to non-invasively detect minimal residual disease (MRD) augmented by biological insights. The company has registrational studies underway, including PREEMPT CRC (>40,000 participants) and PROACT LUNG (up to 20,000 participants), plus multi-cancer research programs such as the Vallania Study (more than 6,200 participants) and additional studies totaling >10,000 paired RWD participants. Freenome intends to use the newly raised funds to advance its pipeline of single-cancer and multi-cancer early detection tests. The company is led by CEO Mike Nolan and is based in San Francisco, CA. Freenome develops a multiomics platform that uses routine blood draws to detect cancer in its earliest stages. Its core product is a blood test for colorectal cancer (CRC) being validated in the large prospective registrational study PREEMPT CRC, which is nearing completion of enrollment. The company plans to commercialize the CRC screening test and expand the platform to detect other cancers, and has reported promising data in pancreatic cancer detection. Freenome combines molecular biology, computational biology, and machine learning to identify disease-associated patterns among circulating cell-free biomarkers. Financially, Freenome announced a $300M Series D and has raised over $800M in total financing since its 2014 founding. The new funding is intended to support commercialization and further development of multi-cancer tests. Freenome has developed a comprehensive multiomics platform to detect cancer early from a routine blood draw, beginning with a colorectal cancer screening test. The platform integrates genomics, transcriptomics, methylomics, and proteomics with advanced computational biology and machine learning to recognize disease-associated patterns among circulating cell-free biomarkers. Freenome launched the PREEMPT CRC FDA registrational clinical trial in May 2020 to support approval of its first front-line blood test for colorectal cancer screening and precancerous lesion detection. The company intends to use proceeds from the financing to accelerate PREEMPT CRC toward approval, reimbursement, and commercialization, advance a pipeline of blood tests for additional cancers, and continue building its proprietary multiomics platform. Financially, Freenome closed an oversubscribed $270 million Series C that brings total financing to over $500 million since the company’s launch. The company is headquartered in South San Francisco, California. Freenome has built a multiomics platform that integrates assays for cell-free DNA, methylation, and proteins with computational biology and machine learning to detect early signs of cancer from a routine blood draw. The company’s first test targets colorectal cancer and uses a multidimensional view of tumor- and immune-derived signatures to improve sensitivity and specificity. Freenome reported promising clinical results at Digestive Disease Week showing high sensitivity and specificity in a cohort of mostly early-stage colorectal cancer patients. The company plans a pivotal validation study and intends to submit to the FDA and CMS under the Parallel Review Program for its colorectal cancer screening application. Proceeds from its recent financing will also fund expansion of laboratory infrastructure and software to support growth and future development. Freenome is headquartered in South San Francisco and was founded in 2014. Freenome is a health-technology company combining machine learning, biology and computer science to develop non-invasive disease screening assays based on cell-free DNA and other analytes. The company has collaborated with more than 25 research partners, including UCSD Moores Cancer Center, UCSF and MGH, and has processed thousands of samples through research and clinical trials. Freenome is working with five pharmaceutical companies to validate its software for clinical trial stratification and precision prescribing. The company is focused on scaling its technology and improving screening accuracy for lung, colorectal, breast and prostate cancers, with plans to address additional cancers and diseases. Proceeds from the Series A financing are being used to accelerate clinical trials, expand research, and advance its first products toward regulatory review. Headquartered in South San Francisco and launched in 2014, Freenome has raised more than $70 million since founding.